AVROBIO Inc
NASDAQ:TECX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AVROBIO Inc
Long-Term Debt
AVROBIO Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AVROBIO Inc
NASDAQ:TECX
|
Long-Term Debt
$43k
|
CAGR 3-Years
-68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$58.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$22.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$50B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Long-Term Debt
$2.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
86%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$106.7m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-18%
|
|
AVROBIO Inc
Glance View
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.
See Also
What is AVROBIO Inc's Long-Term Debt?
Long-Term Debt
43k
USD
Based on the financial report for Dec 31, 2025, AVROBIO Inc's Long-Term Debt amounts to 43k USD.
What is AVROBIO Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
-68%
Over the last year, the Long-Term Debt growth was -89%. The average annual Long-Term Debt growth rates for AVROBIO Inc have been -68% over the past three years .
